The U.S. Food and Drug Administration (FDA) officially granted marketing approval to VIZZ (aceclidine ophthalmic solution 1.44%) as a once-daily, non-invasive pharmacological treatment for presbyopia in adults. This regulatory milestone established VIZZ as the first and only aceclidine-based eye drop approved to improve near vision for up to 10 hours, providing an innovative alternative to traditional reading glasses and surgical procedures.